Cargando…

Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome

BACKGROUND: Polycystic ovary syndrome (PCOS) is an endocrinopathy that affects approximately 10% of reproductive-aged women throughout their lives. Women with PCOS present with heterogeneous symptoms including ovulatory dysfunction, hyperandrogenism, and polycystic ovaries. Therefore, lifelong indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Young-Mo, Choi, Eun Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562722/
https://www.ncbi.nlm.nih.gov/pubmed/26366087
http://dx.doi.org/10.2147/TCRM.S89737
_version_ 1782389200594665472
author Yang, Young-Mo
Choi, Eun Joo
author_facet Yang, Young-Mo
Choi, Eun Joo
author_sort Yang, Young-Mo
collection PubMed
description BACKGROUND: Polycystic ovary syndrome (PCOS) is an endocrinopathy that affects approximately 10% of reproductive-aged women throughout their lives. Women with PCOS present with heterogeneous symptoms including ovulatory dysfunction, hyperandrogenism, and polycystic ovaries. Therefore, lifelong individualized management should be considered. Pharmacological agents commonly used to manage the symptoms are metformin and oral contraceptive pills. Although these medications have been beneficial in treating PCOS symptoms, their efficacy and safety are still not entirely elucidated. This study aimed to report the efficacy and safety of metformin, oral contraceptives, or their combination in the treatment of PCOS and to define their specific individual roles. METHODS: A literature search of original studies published in PubMed and Scopus was conducted to identify studies comparing metformin with oral contraceptives or evaluating the combination of both in PCOS. RESULTS: Eight clinical trials involving 313 patients were examined in the review. The intervention dosage of metformin ranged from 1,000 to 2,000 mg/d and that of oral contraceptives was ethinylestradiol 35 µg and cyproterone acetate 2 mg. Lower body mass index was observed with regimens including metformin, but increased body mass index was observed in monotherapy with oral contraceptives. Administration of metformin or oral contraceptives, especially as monotherapy, had a negative effect on lipid profiles. In addition, there are still uncertainties surrounding the effects of metformin or oral contraceptives in the management of insulin level, although they improved total testosterone and sex hormone-binding globulin levels. In the included studies, significant side effects due to metformin or oral contraceptives were not reported. CONCLUSION: The clinical trials suggest that metformin or oral contraceptives are at least patient convenient, efficacious, and safe for the treatment of PCOS. However, well-designed, prospective, long-term, large-scale, randomized clinical trials are necessary to elucidate the efficacy and safety of metformin, oral contraceptives, or both in the treatment of PCOS, and to elucidate their individual roles in the treatment of this condition.
format Online
Article
Text
id pubmed-4562722
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45627222015-09-11 Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome Yang, Young-Mo Choi, Eun Joo Ther Clin Risk Manag Review BACKGROUND: Polycystic ovary syndrome (PCOS) is an endocrinopathy that affects approximately 10% of reproductive-aged women throughout their lives. Women with PCOS present with heterogeneous symptoms including ovulatory dysfunction, hyperandrogenism, and polycystic ovaries. Therefore, lifelong individualized management should be considered. Pharmacological agents commonly used to manage the symptoms are metformin and oral contraceptive pills. Although these medications have been beneficial in treating PCOS symptoms, their efficacy and safety are still not entirely elucidated. This study aimed to report the efficacy and safety of metformin, oral contraceptives, or their combination in the treatment of PCOS and to define their specific individual roles. METHODS: A literature search of original studies published in PubMed and Scopus was conducted to identify studies comparing metformin with oral contraceptives or evaluating the combination of both in PCOS. RESULTS: Eight clinical trials involving 313 patients were examined in the review. The intervention dosage of metformin ranged from 1,000 to 2,000 mg/d and that of oral contraceptives was ethinylestradiol 35 µg and cyproterone acetate 2 mg. Lower body mass index was observed with regimens including metformin, but increased body mass index was observed in monotherapy with oral contraceptives. Administration of metformin or oral contraceptives, especially as monotherapy, had a negative effect on lipid profiles. In addition, there are still uncertainties surrounding the effects of metformin or oral contraceptives in the management of insulin level, although they improved total testosterone and sex hormone-binding globulin levels. In the included studies, significant side effects due to metformin or oral contraceptives were not reported. CONCLUSION: The clinical trials suggest that metformin or oral contraceptives are at least patient convenient, efficacious, and safe for the treatment of PCOS. However, well-designed, prospective, long-term, large-scale, randomized clinical trials are necessary to elucidate the efficacy and safety of metformin, oral contraceptives, or both in the treatment of PCOS, and to elucidate their individual roles in the treatment of this condition. Dove Medical Press 2015-09-01 /pmc/articles/PMC4562722/ /pubmed/26366087 http://dx.doi.org/10.2147/TCRM.S89737 Text en © 2015 Yang and Choi. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Yang, Young-Mo
Choi, Eun Joo
Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
title Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
title_full Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
title_fullStr Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
title_full_unstemmed Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
title_short Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
title_sort efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562722/
https://www.ncbi.nlm.nih.gov/pubmed/26366087
http://dx.doi.org/10.2147/TCRM.S89737
work_keys_str_mv AT yangyoungmo efficacyandsafetyofmetforminororalcontraceptivesorbothinpolycysticovarysyndrome
AT choieunjoo efficacyandsafetyofmetforminororalcontraceptivesorbothinpolycysticovarysyndrome